
What a Biotech Platform Company Actually Is — and When the Model Fails
Ravi IyerPlatform biotechs sell a repeatable method, not a single drug. The label is doing more work than ever in fundraising, and it does not always hold.
The technology of biology as business.

Platform biotechs sell a repeatable method, not a single drug. The label is doing more work than ever in fundraising, and it does not always hold.

A new documentary reopens the case, and the underlying lesson about verification in diagnostics has not aged a day.

Biotech financing runs on staged proof: seed capital buys discovery data, Series A buys a path to the clinic, and the gap between them kills more companies than any failed trial.

Molecular testing is moving to the point of care. Roche said on December 2, 2025 that its cobas liat Bordetella test received FDA 510(k) clearance and a CLIA waiver, with results in about 15 minutes, per the company. On August 6, 2026, Co-Diagnostics announced a dual 510(k) with a concurrent…

NIH's All of Us Research Program became the world's largest integrated genomic and electronic health record database with its June 30, 2026 release, which per the agency's announcement makes data from more than 747,000 participants available to scientists and includes more than 535,000 whole…

Lab automation in biotech has moved from liquid-handling convenience to process control: a nonlinear model predictive control system developed by Sartorius researchers increased continuous CHO perfusion production by 68% while holding viable cell density at or above 95%, per a September 23, 2026…